Clinical Validation of the RENISCHEM L-FABP POC Assay (SAKURA-POC)
A Study of Contrast-induced Acute Kidney Injury Prediction Using the RENISCHEM L-FABP Assay at the Point-of-Care
Sponsor: Hikari Dx, Inc.
Listed as NCT04864847, this observational or N/A phase trial focuses on Acute Kidney Injury and Contrast-induced Nephropathy and remains ongoing. Sponsored by Hikari Dx, Inc., it has been updated 12 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Aug 2025 — Feb 2026 [monthly]
Recruiting
Status: Active Not Recruiting → Recruiting
-
Apr 2025 — Aug 2025 [monthly]
Active Not Recruiting
-
Dec 2024 — Apr 2025 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jan 2024 — Jul 2024 [monthly]
Recruiting
-
Nov 2023 — Jan 2024 [monthly]
Recruiting
Status: Unknown Status → Recruiting
-
Sep 2023 — Nov 2023 [monthly]
Unknown Status
Status: Not Yet Recruiting → Unknown Status
-
Dec 2021 — Sep 2023 [monthly]
Not Yet Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hikari Dx, Inc.
- Timewell Medical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .